NCT01767493View on ClinicalTrials.gov

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Multiple Sclerosis
Interventions
DRUG

[18F]Florbetapir PET imaging

\[18F\]Florbetapir and PET imaging

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Institute for Neurodegenerative Disorders

OTHER